8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 13, 2025

Accenture plc

(Exact name of Registrant as specified in its charter)

1 Grand Canal Square

Grand Canal Harbour

Dublin 2, Ireland

(Address of principal executive offices)

Registrant’s telephone number, including area code: (353) (1) 646-2000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | | --- | --- || ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | | --- | --- || ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | | --- | --- || ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | | --- | --- |

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On February 13, 2025, Julie Sweet, Chair and Chief Executive Officer of Accenture plc, sent a message to all Accenture people providing an update on her health. A copy of her message is attached to this Current Report on Form 8-K as Exhibit 99.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Document

Exhibit 99

Subject: Providing an update on my health

To: All Accenture People

I am writing to let you know that I was very recently diagnosed with breast cancer. The good news is that the prognosis from my doctor is excellent; the cancer was caught early, and my condition is curable. In addition, a PET scan confirmed that there is no evidence of cancer elsewhere in my body.

I will undergo surgery next week, and the expected treatment afterwards is radiation. Treatment is likely to last 12 to 16 weeks. I have been advised that I will be able to work substantially as normal, leading the day-to-day operations of the company throughout this process. I will, however, curtail my travel during this period. The Board has been briefed and is fully supportive.

We have an incredible Global Management Committee, supported by our amazing teams around the world. I am confident that we will continue to do what we do best – deliver 360° value for our clients, people, shareholders, partners and communities.

As always, I am grateful for all you do each day for our clients and each other.

Best regards,

Julie